Similarly, drug approaches that attempt to downregulate ER function and discount GPER are limited to cancers that are ER+ in nature and are not expected to be significantly efficacious for cancers such as TNBC, which has been shown to be GPER-regulated and not ER-regulated [50]. The gene discussed is GPER1; the disease is cancer.